Abstract 1851
Background
Immune checkpoint inhibitors can cause pneumonitis in lung cancer patients. The role of previous thoracic radiation therapy (TRT) as a risk factor is not clear. Furthermore, some patients show radiation recall pneumonitis (RRP) pattern. In this multicenter retrospective study, we analyzed the relationship of previous TRT and other potential risk factors with nivolumab-induced pneumonitis, and the characteristics of RRP.
Methods
Medical records of non-small cell lung cancer patients, who received nivolumab between December 2015 and March 2017, were retrospectively reviewed. Baseline clinical characteristics, incidence, and risk factors were analyzed at 5 hospitals. Person’s chi-square test and multivariate logistic regression analysis (age, sex, smoking history, treatment history of TRT, and performance status at the start of nivolumab treatment) were conducted to identify potential risk factors. Imaging analysis for RRP was conducted only for patients treated in National Cancer Center Hospital at the moment.
Results
A total of 669 patients were evaluated, and the incidences of all-grade and ≥ grade 2 pneumonitis were 8.9% (60/669) and 7.2% (47/669), respectively. Two (0.3%) patients died due to the pneumonitis. Incidences of pneumonitis were 12.9% (33/256) and 6.5% (27/413) in patients with and without previous TRT, respectively. History of previous TRT was associated with pneumonitis in multivariate analysis [odds ratio, 1.95; 95% confidence interval 1.13-3.34]. Chest imaging by computed tomography of some of those patients showed RRP pattern with pneumonitis infiltration occurring in the radiation field previously treated, and the direct relation was suggested. Incidences of RRP were 4.2% (4/95) among patients with history of previous TRT and 30.8% (4/13) among patients with previous TRT and who developed nivolumab-induced pneumonitis.
Conclusions
Increasing risk of nivolumab-induced pneumonitis was associated with treatment history of TRT. RRP pattern was one of the characteristic radiographic patterns of nivolumab-induced pneumonitis in patients with previous TRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract
4125 - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone
Presenter: Ramon Mohanlal
Session: Poster Display session 1
Resources:
Abstract